The Impact of Baseline Comorbidities and Performance Status on HER2-Targeted Therapy Outcomes.
Akbari, Amir R
Akbari, Amir R
Abstract
We read with great interest the article by Kook et al.,1 comparing adjuvant trastuzumab plus pertuzumab (TP) versus trastuzumab alone (T) in patients with HER2-positive breast cancer who achieved a pathologic complete response (pCR) following neoadjuvant chemotherapy. While the authors concluded that there was no significant difference in recurrence-free survival (RFS) or distant recurrence-free survival (DRFS) between the 2 regimens, we believe the study may have overlooked an important confounding variable: baseline comorbidities and performance status.
MIDER Authors
Citations
Altmetric:
Date
Type
Article
Subject
Comorbitities, Performance, Outcomes
Collections
Citation
Akbari, A.R. and Alam, B. (2025) ‘The Impact of Baseline Comorbidities and Performance Status on HER2-Targeted Therapy Outcomes’, Clinical breast cancer [Preprint].
Journal / Source Title
DOI
PMID
Publisher
Clinical Breast Cancer